Literature DB >> 14622478

Interstitial laser coagulation treatment of benign prostatic hyperplasia: is it to be recommended?

M Pilar Laguna1, Gerasimos Alivizatos, Jean J M C H De La Rosette.   

Abstract

PURPOSE: To update the clinical data on the treatment of benign prostatic hyperplasia (BPH) by interstitial laser coagulation (ILC).
MATERIAL AND METHODS: In addition to recent review articles, original papers published during the last 2 years were surveyed. The focus was on prospective, particularly randomized, trials and on those with long-term follow-up.
RESULTS: Interstitial laser coagulation is feasible, although considerable variability is observed in the results. Operative complications are minimal, but the postoperative catheterization time is relatively long. Irritative symptoms can last for a long time, and the rate of urinary infections is as high as 35%. There also is significant variability in the urodynamic results. The technique seems to be more effective in patients with mild bladder outlet obstruction at baseline. The retreatment rate at 1 year is as high as 15%, and higher rates, as much as 40%, are described at 3 years. When compared in a randomized fashion with transurethral resection of the prostate (TURP), the postoperative period is shorter after TURP and the retreatment rate (early and late) is higher after ILC.
CONCLUSIONS: Interstitial laser coagulation is superior to TURP in terms of operative morbidity, but postoperative morbidity is higher after ILC. Long-term durability has not been properly documented, and randomized studies show a higher retreatment rate after ILC than after TURP. The technique is recommended for those patients with bleeding disorders necessitating an interventional therapy.

Entities:  

Mesh:

Year:  2003        PMID: 14622478     DOI: 10.1089/089277903322518590

Source DB:  PubMed          Journal:  J Endourol        ISSN: 0892-7790            Impact factor:   2.942


  8 in total

Review 1.  New laser treatment approaches for benign prostatic hyperplasia.

Authors:  Nathaniel M Fried
Journal:  Curr Urol Rep       Date:  2007-01       Impact factor: 3.092

2.  [Benign prostatic syndrome (BPS). Ablative treatments].

Authors:  O Reich; M Seitz; C Gratzke; B Schlenker; A Bachmann; C Stief
Journal:  Urologe A       Date:  2006-06       Impact factor: 0.639

3.  [Thulium:YAG vaporesection of the prostate. First results].

Authors:  T Bach; T R W Herrmann; R Ganzer; A Blana; M Burchardt; A J Gross
Journal:  Urologe A       Date:  2009-05       Impact factor: 0.639

Review 4.  Laser treatment of symptomatic benign prostatic hyperplasia.

Authors:  Ehab A Elzayat; Mostafa M Elhilali
Journal:  World J Urol       Date:  2006-03-04       Impact factor: 4.226

Review 5.  Laser treatment of benign prostatic hyperplasia.

Authors:  Rainer M Kuntz
Journal:  World J Urol       Date:  2007-05-25       Impact factor: 3.661

6.  RevoLix vaporesection of the prostate: initial results of 54 patients with a 1-year follow-up.

Authors:  Thorsten Bach; Thomas R W Herrmann; Roman Ganzer; Martin Burchardt; Andreas J Gross
Journal:  World J Urol       Date:  2007-05-25       Impact factor: 3.661

7.  The evaluation of tissue mass loss in the incision line of prostate with benign hyperplasia performed using holmium laser and cutting electrode.

Authors:  Mariusz Szewczyk; Dorota Jesionek-Kupnicka; Marek Ireneusz Lipiński; Piotr Lipinski; Waldemar Różański
Journal:  Cent European J Urol       Date:  2014-08-18

8.  Transperineal Laser Ablation Treatment for Lower Urinary Tract Symptoms Due to Benign Prostatic Obstruction: Protocol for a Prospective In Vivo Pilot Study.

Authors:  Rob A A van Kollenburg; Luigi A M J G van Riel; Paul R Bloemen; Jorg R Oddens; Theo M de Reijke; Harrie P Beerlage; Daniel Martijn de Bruin
Journal:  JMIR Res Protoc       Date:  2020-01-21
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.